On the question of antigens by Гаркава, Катерина Григорівна
UDC  616-097 (043.2) 
 
ON THE QUESTION OF ANTIGENS 
 
K.G. GARKAVA  
National Aviation University, Kiev 
 
The paper discusses the issues of increasing the antigen under the influence of 
negative factors of the environment and in obtaining biologically active compounds 
using recombinant techniques. 
Keywords: antigens, adducts, recombinant biologically active compounds. 
 
Introduction. The influence of negative environmental factors increases the 
spectrum of antigen (AG) unpredictability. Antigens are substances that carry genetic 
features of foreignness and when administered to the organism induce the 
development of immunological reactions: synthesis of antibodies, the cellular 
immune response, immune tolerance and immunological memory. 
Antigens are classified into: 





2. Incomplete antigens (haptens) – simple organic substances, but in some cases 
with complex chemical structure. Inorganic substances. 
• complex haptens (polysaccharides, polypeptides, lipids, nucleic acids); 
• simple haptens (monosaccharides, simple organic and inorganic substances) 
[8, 9, 13]. 
Can enzymes be antigens? Works of Fedoriche V.N. 1988-2011 have shown that 
antibodies are produced to the enzymes lactate dehydrogenase, creatine 
phosphokinase, esterases and DNA-ase. He has shown that the dynamics of 
antibodies production to lactate dehydrogenase and esterase can help to trace the 
course of the small focal and macrofocal acute myocardial infarction and its outcome. 
Perhaps one of the factors reducing the activity of enzymes is their acquisition of 
antigen properties. It is known that the activity of fibrinolytic enzyme streptokinase is 
also reduced for the same reasonх [11, 12]. 
Antigens characteristics 
Antigens are characterized by: 
• foreignness – antigens are the carrier of genetically foreign information to the 
body; 
• antigenicity – the ability to induce the production f antibodies. Proteins with 
the dextrorotatory isomer of the amino acids in the macrophage is not processed and 
do not include the transmission of antigenic information; 
• immunogenicity – the ability to create the immunity; 
• specificity – the antigenic characteristics by which antigens are different from 
each other. 
Antigens – are macromolecular substances. Their valence depends on the 
molecular weight. Antigen valency is a quantity of determinant groups on an antigen 
molecule or number of antibody molecules, which can o nect to them. For instance, 
egg albumin has a valence 5, serum albuminn – 6, thyroglobulin – 40. 
Antigen properties depend on the stiffness of the structure and spatial 
configuration of their molecules. Stiffness of struc ure is given to antigenic 
determinant by three amino acid – tyrosine, tryptophan and phenylalanine. 
The specificity of antigen – is the antigenic characteristics by which antigens are 
different from each other. 
The are following types of antigen specificity: 
• species specificity – is the specificity, in which members of one species of 
organisms differ from another species; 
• group specificity – is the specificity, which causes the differences among 
individuals of the same species of organisms (blood group, histocompatibility 
antigens); 
• type specificity – it often relates to the specificity of microbial species. 
Botulinum toxin synthesized in nature are divided into types A, B, C, D, E. 
• organ or tissue specificity is proved to all organs d tissues; 
• organoid specificity defines the antigenic differenc s of cell organelles 
(nucleus, ribosomes, mitochondria) 
• hetero specificity – is common antigens for members of different species. For 
instance, Forsman antigen is present in erythrocytes of sheep, horses, dogs, cats, mice 
and chickens, but not in humans, monkeys, rabbits, ra  or ducks; 
• functional specificity – is related to the function f the protein molecule. For 
instance, human and bovine insulin perform the same function, but differ in one 
amino acid; 
• stage specificity – is antigenic characteristics of organs and tissues, which are 
at certain stages of individual development and embryogenesis. For instance, α-
fetoprotein is the antigen present in fetal liver but absent in the adult organism; 
• hapten specificity – is due to the specificity of a hapten groups; 
• pathological – is related to properties of antigens in organ and tissue with 
pathological changes. 
All the antigen specificity is due to the active chemical group. The antigenicity 
of proteins is due to the primary and conformational structure of the molecule. 
Variation of the chemical composition and structure of the antigen molecule changes 
its specificity. Replacement of a single amino acid in the polypeptide chain changes 
an antigen (e.g., human or swine insulin). It is know  that small changes of surface 
groups, for example, when NO2 and J2 are introduced into a protein molecule 
followed by methylation, acetylation and blockade of the surface carboxyl and other 
antigenic groups, it will change the antigen specificity. Iodization of proteins leads to 
a change in the species specificity.  
 
Cross-reactive antigens 
Cross-reactive antigens general, antigens of micro- and macro-organisms. 
Cross-microbial antigens can induce the formation of autoantibodies in the 
mammalian organisms to their tissues.  
Streptococcus of group A has cross-reactive antigens with cells of skeletal and 
smooth muscle of endocardium, heart valves and kidneys. 
β-hemolytic streptococcus has similar antigens with connective tissue of heart 
muscle and blood vessels. 
Lipopolysaccharide of E. coli strain 086 is similar to erythrocytic izoantigen B. 
Nucleoproteins of streptococcus are similar to the nucleoprotein of the collagen. 
Streptococcus and Staphylococcus have cross – reactive antigens with HLA-
antigens [8, 9, 13]. Number of antigens in nature increases due to the fact that many 
not antigenic substances in connection with other materials become antigens. 
Adducts 
The adduct – is the result of the covalent attachment of one molecule to another. 
Some adducts cause permanent blocking or inhibiting of enzymes. Adducts with 
DNA may have mutagenic or carcinogenic properties. Many allergens are adducts 
known as haptens. The mechanisms of formation of adducts are very diverse – some 
are formed as result of the capture of free radicals, others – when nucleophilic and 
electrophilic substances are combined. 
Natural adducts 
Natural adducts can be formed during connection of chemically active groups of 
different nature with cells, proteins and nucleic acids. For example, aminopyrine, 
quinidine, phenolphthalein, picric acid, and toxic organophosphorus compounds, 
antibiotics, adsorbed on blood corpuscles, proteins a d peptides may cause 
leukopenia, anemia and thrombocytopenia. These proteins induce production 
antibodies of 3 types: 
1. Against the hapten determinant. 
2. Against self determinants of the protein molecule. 
3. Against those chemical modifications that occurred after the accession of the 
active chemical groups [9, 13]. 
Chemical adducts 
Modification of proteins derived from polyethyleneglycol to impart stability and 
prolonging their action, solubility in organic solvents commonly used in 
biotechnology. Such protein adduct consists of two macromolecular fragments - the 
protein and polymer blends and the properties of each of them. As the polymer 
fragment using dextran. They are used for developing new dosage forms as vehicles 
for transport to the cells of the target substances insoluble in water. What antigens are 
formed on them? – The question remains opened [4, 10, 14]. 
Genetically modified organism 
Genetically modified organism – is an organism, which has the alien gene 
introduced to it natural set of genes by genetic engineering methods. 
Obtaining of recombinant α2-interferon  
As a result of plasmid technology that is highly productive, but has a serious 
disadvantage: obtained interferon has a different oligomeric structures that are absent 
in natural interferon. 
In contrast to the plasmid technology, synthesis of α2-recombinant interferon 
based on the use of bacteriophage as an amplifier, into the genome of which the gene 
of interferon is injected by genetic engineering method. Bacteriophage (virus of 
bacteria), infecting bacterial cell, multiplies in it by copying DNA and built-in it 
interferon gene, and synthesizes proteins, including interferon. At a certain stage of 
development bacteriophage lyses the bacterial cell. Interferon releases into a culture 
fluid in water-soluble state, without forming insolub e forms. Synthesis is organized 
in such way so that interferon accumulates extracellularly in the culture medium 
therefore does not constitute an "inclusion bodies", a  occurs in plasmid technology 
of obtaining an interferon [1-3, 6]. 
A Question: how similar is a structure of natural and recombinant leukocyte 
inteferon – remains open, although they have similar functional activity. 
Recombinant technology is also used to obtain insuli . 
Question – how similar is antigenic structure of biologically active compounds 
of natural and recombinant origin remains open, although they are similar by 
functional activity. 
The transgenic vaccines 
Recombinant technology is used to produce vaccines against hepatitis B and 
Lyme disease [5-7]. 
The creation of DNA-vaccine is predominantly carried out with bacterial 
plasmids – small stable circular DNA which are located outside chromosomes. 
Plasmids themselves do not provoke infection. In fact they are only used as a vector, 
which is a delivery vehicle. To cause the required immune response, isolated from 
bacteria plasmid are modified introducing specific changes in the DNA structure 
sewing in genes encoding one or more specific protein antigens, which are produced 
by a specific bacterium or a virus. Also there are incorporation of genes required for 
the expression of the whole structure. At the same ti , the DNA fragments which 
are responsible for the restoration and reproduction of infection, are not carried into 
the plasmid. 
There is a risk that the foreign DNA can harm the human DNA, as well as 
there is an assumption that at this immunization the immune response against self 
antigens can develop and strengthen, ie autoimmune reaction, which can then move 
to self-aggression. Also the introduction of foreign DNA can cause mutations in the 
genome of an organism and change in ontogeny [15-18]. 
CONCLUSION 
A wide range of natural and man-made antigens lead to either stimulation or 
inhibition of the immunological reaction, or generat s tolerance. 
• Inhibition leads to an increase in infectious diseases and cancer. 
• Stimulation leads to the development of autoimmune diseases and 
autoaggression. 
• Tolerance results in enhanced persistence of infectous agents. 
• Increased antigenic stimulation enhances apoptosis of immunocompetent cells 
and leads to the deterioration of the immune system. 
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